The adjustment in price target by a major analyst like Morgan Stanley can have a nuanced impact on Pharvaris's stock. While maintaining an Overweight rating indicates continued confidence in the company's prospects, the reduction in price target could signal a slight adjustment in expectations. This might lead to mixed reactions in the short term, as investors digest the implications of the new target.